Trial Profile
A Study of Chlorambucil Plus MabThera as Induction Therapy Followed in Responders by Maintenance Therapy Versus Observation on Response Rate in Patients greater than or equal to 60 Years With Previously Untreated Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 May 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 13 Dec 2011 Interim results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.